抗生物質の世界市場：画期的医薬品の市場機会及び商用化...市場調査レポートについてご紹介

1 Table of Contents
1 Table of Contents 2
1.1 List of Tables 3
1.2 List of Figures 3
2 Executive Summary 4
2.1 A Low Degree of First-in-Class Innovation in a Very Active Pipeline 4
2.2 A low Diversity in the Mechanisms of Action of First-in Class Targets 4
2.3 A High Number of Deals Involving Antibiotics, but Few involving First-in-Class Targets 5
3 The Case for Innovation in Antibiotic Development 6
3.1 Diversification of Molecular Targets 6
3.2 Growing Opportunities for Biological Products 6
3.3 Innovative First-in-Class Product Developments Remain Attractive 7
3.4 Regulatory and Reimbursement Policy Shifts Favor First-in-Class Product Innovation 7
3.5 Financial Incentives 8
3.6 Report Guidance 8
4 Clinical and Commercial Landscape 9
4.1 Etiology 9
4.1.1 Adherence to Host Cells and Biofilm Formation 9
4.1.2 Toxins and Toxin Secretion Systems 11
4.1.3 Ability to Evade the Host Immune System 12
4.2 Pathophysiology 12
4.3 Traditional Antibiotic Development and Associated Mechanisms of Action 13
4.3.1 Overview 13
4.3.2 DNA Synthesis and Transcription Machinery 15
4.3.3 RNA Synthesis Arrest 15
4.3.4 Disruption of Cell Wall Stability of Formation 16
4.3.5 Disruption of Cell Membrane Formation and Stability 17
4.3.6 Disruption of Cell Metabolism 17
4.3.7 Inhibition of Protein Synthesis 17
4.4 Mechanisms of Antibiotic Resistance 19
4.4.1 Target Modification 19
4.4.2 Efflux Pumps 19
4.4.3 Enzymatic Inactivation of Antibiotics 20
4.4.4 Changes to Outer Membrane Permeability 20
4.5 Treatment Algorithm 21
4.6 The Future of Antibiotic Development 22
5 Assessment of Pipeline Product Innovation 26
5.1 Antibiotic Pipeline by Phase, Molecule Type and Molecular Target 26
5.2 Antibiotic Pipeline by Mechanism of Action 27
5.3 First-in-Class Pipeline Programs Targeting Novel Molecular Targets 31
6 First-in-Class Target Evaluation 35
6.1 Pipeline Programs which Target Lipoteichoic Acid or Lipoteichoic Acid Synthase 35
6.2 Pipeline Programs which Target Pseudomonas Aeruginosa Lectins LecA and LecB 37
6.3 Pipeline Programs which Target Sortase A 38
6.4 Pipeline Programs which Target Pyruvate Kinase 41
6.5 Pipeline Programs which Target UDP-N-acetylglucosamine 2-epimerase 43
6.6 Pipeline Programs which Target Peptide Deformylase 44
6.7 Pipeline Programs which Target LpxC enzyme 46
6.8 Pipeline Programs which Target Sialic Acid Transporter TRAP 48
6.9 Pipeline Programs which Target Methionine tRNA Ligase 49
6.10 Pipeline Programs which Target FtsZ Protein 51
6.11 Pipeline Programs which Target Clostridium Difficile Toxins A and B 53
6.12 Pipeline Programs which Target Staphylococcus Enterotoxins A and B 55
6.13 Pipeline Programs which Target NDM-1 Beta Lactamase 56
6.14 Pipeline Programs which Target DegS Serine Endoprotease 57
6.15 Pipeline Programs which Target A Disintegrin and Metalloproteinase 10 59
6.16 Pipeline Programs which Target Translocase-1 60
7 Patent Filings 63
8 Deals and Strategic Consolidations 65
8.1 Industry Wide First-in Class Deals 65
8.2 Antibiotics Deals Landscape 66
8.3 Licensing Deals 67
8.3.1 Molecule Type and Mechanism of Action 69
8.4 Co-Development Deals 72
8.4.1 Molecule Type and Mechanism of Action 73
8.5 First-in-Class Programs Not Involved in Licensing or Co-Development Deals 77
9 Appendix 79
9.1 Abbreviations 79
9.2 References 79
9.3 Contact Us 91
9.4 Disclaimer 91